• Age ≥ 18 years at the time of study entry

• Capable of understanding and complying with the protocol requirements and must have signed the informed consent document

• ECOG performance status of 0 or 1 or KPS of at least 80%

• Life expectancy ≥ 12 weeks

• Histologically confirmed advanced (not amenable to curative surgery or radiation therapy) or metastatic (stage IV) RCC with predominantly clear cell component (sarcomatoid differentiation \<50%)

• a. Patients with localized RCC who develop metastatic disease post definitive nephrectomy, with or without systemic therapy in the adjuvant setting, are eligible

• Patients with favorable, intermediate, or poor risk categories as defined by the MSKCC Prognostic Model or the IMDC consortium (Appendix A) will be eligible for the study

• Evidence of measurable disease per RECIST 1.1 (i.e., ≥1 malignant tumor mass ≥10 mm with spiral CT scan using a 5 mm or smaller contiguous reconstruction algorithm)

• Adequate normal organ, marrow and coagulation function based on below labs within 14 days before first dose of study treatment:

‣ Hgb ≥ 9.0g/dL

⁃ White blood count ≥ 2500/ µL

⁃ ANC ≥1 x 109/L (≥1500/L) without growth factor support

⁃ Plt count ≥ 100 x 109 /L (≥100,000/L) without transfusion

⁃ Total serum bilirubin ≤1.5 x institutional ULN; Gilbert's disease, Total serum bilirubin ≤3 x institutional ULN

⁃ Serum transaminases (AST/ALT) ≤3 x the institutional ULN; ALP ≤5 x the institutional ULN with documented bone metastasis

⁃ Serum albumin ≥ 2.8 g/dl

⁃ PT/INR or PTT test ≥ 1.3 x the laboratory ULN

⁃ Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30 mL/min

‣ UPCR ≤ 1mg/mg (≤113.2 mg/mmol) or 24-h urine protein ≤ 1 g

• Representative FFPE tumor block (archival or recent acquisition) with an associated anonymized pathology report must be available for central testing.

• Recovery to baseline or ≤ Grade 1 (CTCAE v. 5.0) from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapy.

• Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment (See Appendix E).

• Female subjects of childbearing potential must not be pregnant at screening (negative serum or urine pregnancy test within 2 weeks prior to the first dose of therapy). Female subjects are considered to be of childbearing potential unless one of the following criteria are met:

‣ Documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)

⁃ Documented postmenopausal status (defined as 12 months of amenorrhea in a woman \> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \< 55 years-of-age must have a serum FSH level \> 40 mIU/mL to confirm menopause).

⁃ Note: documentation may include review of medical records, medical examinations, or medical history interview by the study site